Tracers / [90Y]Y-DOTA-TOC

[90Y]Y-DOTA-TOC

Also written as DOTATOC; Y-90-DOTATOC; DOTA-TOC
Radionuclide
Y-90 t½ 3843.6 min
Modality
Therapy
Production route
Stage
Syntheses indexed
19

What it is

Compound class
DOTA-conjugated somatostatin analog (radiolabeled peptide, DOTATOC)
Target / mechanism
Somatostatin receptor (SSTR) targeting PMID 39142827
Clinical application
Peptide receptor radionuclide therapy (PRRT) for somatostatin receptor-expressing tumors, including neuroendocrine tumors, pheochromocytoma/paraganglioma, and meningioma PMID 35450421
Theranostic pair
<a href="/tracers/ga68-dotatoc/">ga68-dotatoc</a>

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesiscustom manifoldnone96.2 ± 4.9%>99% TLC, >97% HPLCDOTATOC
Gamma Servizi s.r.l., Pavia, Italy
29097938
2017 Contrast Media Mol Imaging
a manually assembled system consisting of tubes, valves, and syringes — an average radiochemical yield ... of 96.2 ± 4.9% (n = 77) ... for 90Y ... DOTATOC
ADD-2
Amercare
custom manifoldnone90.3 ± 5.6%>98%DOTATOC
Gamma Servizi s.r.l., Pavia, Italy
29097938
2017 Contrast Media Mol Imaging
The radiolabelling was performed by using an ADD-2 (Amercare, Thame, UK), a prototype of a semiautomatic dose dispenser device — the average RCYs were 90.3 ± 5.6% (n = 63) for 90Y-DOTATOC
Modular-Lab EAZY
Eckert & Ziegler
vendor cassetteSPE82.0 ± 8.4%>97%DOTATOC
Gamma Servizi s.r.l., Pavia, Italy
29097938
2017 Contrast Media Mol Imaging
Modular-Lab Eazy automatic synthesizer, disposable cassettes (C0-YDOTAPEP-CM, C0-LUDOTAPEP-CM, C0-YDOTAPSMA-CM, and C0-LUDOTAPSMA-CM), hardware, and reagent kits were supplied by Eckert & Ziegler Eurotope GmbH (Berlin, Germany) — average RCYs of 82.0 ± 8.4% (n = 24) ... for 90Y- ... DOTATOC ... were achieved
DOTATOC41356201
2026 Theranostics
DOTATOC39142827
2024 J Nucl Med
38324106
2024 Endocrine
35450421
2022 Front Endocrinol (Lausanne)
Manual synthesis
GE HealthCare
DOTA-TOC31107537
2019 Mutagenesis
DOTA-TOC was labelled with 90Y (GE Healthcare, Braunschweig, Germany) as previously described (12).
30854332
2019 Front Oncol
Manual synthesis96.2 ± 4.9>99% TLC, >97% HPLCDOTATOC
Gamma Servizi s.r.l., Pavia, Italy
29097938
2017 Contrast Media Mol Imaging
Manual labelling was carried out using telescopic tongs and dedicated poly(methyl methacrylate) (PMMA) shielding for syringes and vials. — The mean radiochemical yields for 90Y-DOTATOC were 96.2 ± 4.9%
ADD-2
Amercare
custom manifold90.3 ± 5.6>98%DOTATOC
Gamma Servizi s.r.l., Pavia, Italy
29097938
2017 Contrast Media Mol Imaging
The radiolabelling was performed by using an ADD-2 (Amercare, Thame, UK), a prototype of a semiautomatic dose dispenser device — 90.3 ± 5.6%, and 82.0 ± 8.4%
Modular-Lab EAZY
Eckert & Ziegler
vendor cassetteSPE82.0 ± 8.4>97%DOTATOC
Gamma Servizi s.r.l., Pavia, Italy
29097938
2017 Contrast Media Mol Imaging
Modular-Lab Eazy automatic synthesizer, disposable cassettes (C0-YDOTAPEP-CM, C0-LUDOTAPEP-CM, C0-YDOTAPSMA-CM, and C0-LUDOTAPSMA-CM), hardware, and reagent kits were supplied by Eckert & Ziegler Eurotope GmbH (Berlin, Germany). — average RCYs of 82.0 ± 8.4% (n = 24) and 83.1 ± 5.7% (n = 26) for 90Y- and 177Lu-DOTATOC, respectively
42579511
2026 Endocr Relat Cancer
42555490
2026 Hell J Nucl Med
42554825
2026 Eur J Nucl Med Mol Imaging
31806775
2020 J Nucl Med
27890514
2017 Rev Esp Med Nucl Imagen Mol
19601842
2009 Curr Pharm Des
9430472
1997 J Nucl Med

Need this precursor?We can point you to suppliers for [90Y]Y-DOTA-TOC, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 38 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. | Stage 28: added indication(s) onc-ppgl from consolidated missing-rubric review.